Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | XIAP | P98170 | 2/20 | 0.32 |
| ▸ | BIRC3 | Q13489 | 2/20 | 0.32 |
| ▸ | BIRC2 | Q13490 | 2/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12832009 | 0.93 | CYP3A4 (0.36) | CTSBCYP3A4CTSS | |
| SCHEMBL12831954 | 0.92 | CYP3A4 (0.36) | CTSBCYP3A4BTKADRB3ADRA2B | |
| SCHEMBL12831781 | 0.92 | CYP3A4 (0.36) | CTSBCYP3A4BTKCTSS | |
| SCHEMBL12831780 | 0.90 | CYP3A4 (0.37) | CTSBCYP3A4CTSS | |
| SCHEMBL12844263 | 0.89 | CYP3A4 (0.39) | CTSBCYP3A4ADRB3ADRA2BADRA2C | |
| SCHEMBL7873797 | 0.89 | CYP3A4 (0.39) | CTSBCYP3A4ADRB3ADRA2BADRA2C | |
| SCHEMBL13071411 | 0.88 | CYP3A4 (0.38) | CTSBCYP3A4 | |
| SCHEMBL12831777 | 0.87 | CYP3A4 (0.34) | CTSBCYP3A4 | |
| SCHEMBL13071881 | 0.86 | CYP3A4 (0.37) | CTSBCYP3A4CTSSMEN1 | |
| SCHEMBL13071888 | 0.86 | CYP3A4 (0.39) | CTSBCYP3A4BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048862-B2 | Macrocyclic inhibitors of hepatitis C virus replication | INTERMUNE, INC. (US) | 2011-11-01 | — | — | US | disclosed |
| WO-2009142842-A9 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| WO-2009142842-A2 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| US-20090269305-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090269305-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | CTSB 486/4885CYP3A4 704/4885XIAP 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.